X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/secura-bio-announces-the-addition-of-two-new-board-of-directors-members-302008563.html
https://endpts.com/secura-bio-to-keep-offering-blood-cancer-drug-despite-negative-odac-vote-os-questions/
https://www.prnewswire.com/news-releases/secura-bio-inc-receives-orphan-drug-designation-in-europe-for-duvelisib-for-the-treatment-of-patients-with-peripheral-t-cell-lymphoma-301713925.html
https://www.fiercepharma.com/pharma/fda-threatens-clamp-down-another-pi3k-blood-cancer-drug-time-full-approval
https://endpts.com/fda-adcomm-takes-down-secura-bios-leukemia-drug-after-failed-trial-with-potential-os-detriment/
https://www.fiercepharma.com/pharma/fda-puts-microscope-2-more-cancer-accelerated-approvals-without-voluntary-withdrawals
https://endpts.com/pi3k-inhibitor-hit-with-an-increased-death-risk-warning-from-fda-after-final-trial-results-emerge/
https://www.prnewswire.com/news-releases/secura-bio-announces-the-presentation-of-new-copiktra-duvelisib-data-for-the-treatment-of-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphomas-ptcl-301444094.html
https://www.prnewswire.com/news-releases/secura-bio-announces-copiktra-duvelisib-strategic-focus-on-t-cell-lymphoma-and-voluntary-us-withdrawal-of-the-relapsed-or-refractory-follicular-lymphoma-indication-301436834.html
https://www.prnewswire.com/news-releases/secura-bio-announces-copiktra-duvelisib-strategic-focus-on-t-cell-lymphoma-and-voluntary-us-withdrawal-of-the-relapsed-or-refractory-follicular-lymphoma-indication-301436834.html
Market Place
Share 
